220 related articles for article (PubMed ID: 33859804)
1. Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.
Vara BA; Levi SM; Achab A; Candito DA; Fradera X; Lesburg CA; Kawamura S; Lacey BM; Lim J; Methot JL; Xu Z; Xu H; Smith DM; Piesvaux JA; Miller JR; Bittinger M; Ranganath SH; Bennett DJ; DiMauro EF; Pasternak A
ACS Med Chem Lett; 2021 Apr; 12(4):653-661. PubMed ID: 33859804
[TBL] [Abstract][Full Text] [Related]
2. Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1.
Zhou L; Ye X; Wang K; Shen H; Wang T; Zhang X; Jiang S; Xiao Y; Zhang K
Bioorg Chem; 2023 Sep; 138():106682. PubMed ID: 37339563
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Wu F; Li H; An Q; Sun Y; Yu J; Cao W; Sun P; Diao X; Meng L; Xu S
Eur J Med Chem; 2023 Jun; 254():115355. PubMed ID: 37062169
[TBL] [Abstract][Full Text] [Related]
4. The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.
Malchow S; Korepanova A; Panchal SC; McClure RA; Longenecker KL; Qiu W; Zhao H; Cheng M; Guo J; Klinge KL; Trusk P; Pratt SD; Li T; Kurnick MD; Duan L; Shoemaker AR; Gopalakrishnan SM; Warder SE; Shotwell JB; Lai A; Sun C; Osuma AT; Pappano WN
ACS Chem Biol; 2022 Mar; 17(3):556-566. PubMed ID: 35188729
[TBL] [Abstract][Full Text] [Related]
5. Discovery of quinazoline HPK1 inhibitors with high cellular potency.
Toure M; Johnson T; Li B; Schmidt R; Ma H; Neagu C; Lopez AU; Wang Y; Guler S; Xiao Y; Henkes R; Ho K; Zhang S; Chu CL; Gundra UM; Porichis F; Li L; Maurer CK; Fang Z; Musil D; DiPoto M; Friis E; Jones R; Jones C; Cummings J; Chekler E; Tanzer EM; Huck B; Sherer B
Bioorg Med Chem; 2023 Sep; 92():117423. PubMed ID: 37531921
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).
Linney ID; Kaila N
Expert Opin Ther Pat; 2021 Oct; 31(10):893-910. PubMed ID: 33956554
[No Abstract] [Full Text] [Related]
7. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
[TBL] [Abstract][Full Text] [Related]
8. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Taniguchi T; Umezaki Y; Nakazawa Y; Uesugi S; Mori K; Horiuchi T; Obuchi W; Minami M; Shimada T; Wada C; Yoshida T; Higuchi S
Eur J Pharmacol; 2023 Dec; 961():176184. PubMed ID: 37944847
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).
Chan BK; Seward E; Lainchbury M; Brewer TF; An L; Blench T; Cartwright MW; Chan GKY; Choo EF; Drummond J; Elliott RL; Gancia E; Gazzard L; Hu B; Jones GE; Luo X; Madin A; Malhotra S; Moffat JG; Pang J; Salphati L; Sneeringer CJ; Stivala CE; Wei B; Wang W; Wu P; Heffron TP
ACS Med Chem Lett; 2022 Jan; 13(1):84-91. PubMed ID: 35059127
[TBL] [Abstract][Full Text] [Related]
11. The development of small-molecule inhibitors targeting HPK1.
Zhou L; Wang T; Zhang K; Zhang X; Jiang S
Eur J Med Chem; 2022 Dec; 244():114819. PubMed ID: 36209628
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
Zeng S; Wu M; Jin Y; Ye Y; Xia H; Chen X; Che J; Wang Z; Wu Y; Dong X; Chen Y; Huang W
Eur J Med Chem; 2024 Mar; 267():116206. PubMed ID: 38350360
[TBL] [Abstract][Full Text] [Related]
13. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.
Chen H; Guan X; He C; Lu T; Lin X; Liao X
Expert Opin Ther Targets; 2024 Apr; 28(4):237-250. PubMed ID: 38650383
[TBL] [Abstract][Full Text] [Related]
14. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Shi H; Tang H; Li Y; Chen D; Liu T; Chen Y; Wang X; Chen L; Wang Y; Xie H; Xiong B
Eur J Med Chem; 2023 Feb; 248():115064. PubMed ID: 36621137
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
Zhu Q; Chen N; Tian X; Zhou Y; You Q; Xu X
J Med Chem; 2022 Jun; 65(12):8065-8090. PubMed ID: 35696642
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
Wang MS; Wang ZZ; Li ZL; Gong Y; Duan CX; Cheng QH; Huang W; Yang GF
J Med Chem; 2023 Jan; 66(1):611-626. PubMed ID: 36542759
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.
Zeng S; Zeng M; Yuan S; He L; Jin Y; Huang J; Zhang M; Yang M; Pan Y; Wang Z; Chen Y; Xu X; Huang W
Bioorg Chem; 2023 Oct; 139():106728. PubMed ID: 37536217
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors.
Fu S; Wei J; Li C; Zhang N; Yue H; Yang A; Xu J; Dong K; Xing Y; Tong M; Shi X; Xi Z; Wang H; Hou Y; Zhao Y
Bioorg Chem; 2024 Jul; 148():107454. PubMed ID: 38795581
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Zhang J; Li Y; Tang H; Zhou Q; Tong L; Ding J; Xie H; Xiong B; Liu T
Bioorg Chem; 2023 Nov; 140():106811. PubMed ID: 37659145
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.
Ye Q; Liu K; Ye HF; Pan J; Sokolsky A; Wang A; Zhang K; Hummel JR; Kong L; Behshad E; He X; Conlen P; Stump K; Ye M; Diamond S; Covington M; Yeleswaram S; Atasoylu O; Vechorkin O; Yao W
ACS Med Chem Lett; 2023 Jan; 14(1):5-10. PubMed ID: 36655125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
